ERBB2 and breast cancer: PI3K/AKT survival and RAS/MAPK proliferation pathways are the major signaling pathways activated by ERBB2 heterodimers30, thus we initially investigated their phosphorylation kinetics in response to treatments with Abs in SK-Br3 human breast cancer cells.